Cited by 764Colorectal Cancer Surgical TreatmentsColorectal and Anal CarcinomasGastric Cancer Management and Outcomes

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Primary Tumor Response to Preoperative Chemoradiation With or Without Oxaliplatin in Locally Advanced Rectal Cancer: Pathologic Results of the STAR-01 Randomized Phase III Trial

Open access

Aschele, Carlo, Cionini, Luca, Lonardi, Sara, Pinto, Carmine, Cordio, Stefano, Rosati, Gerardo, Artale, Salvatore, Tagliagambe, Angiolo, Ambrosini, Giovanni, Rosetti, Paola, Bonetti, Andrea, Negru, Maria Emanuela, Tronconi, Maria Chiara, Luppi, Gabriele, Silvano, Giovanni, Corsi, Domenico Cristiano, Bochicchio, Anna Maria, Chiaulon, Germana, Gallo, Maurizio, Boni, Luca·2011·Journal of Clinical Oncology

DOI 10.1200/jco.2010.34.4911

Open this paper in CoChat — free account Open PDF

Abstract

Purpose: To investigate oxaliplatin combined with fluorouracil-based chemoradiotherapy as preoperative treatment for locally advanced rectal cancer. Patients and Methods: Seven hundred forty-seven patients with resectable, locally advanced (cT3-4 and/or cN1-2) adenocarcinoma of the mid-low rectum were randomly assigned to receive pelvic radiation (50.4 Gy in 28 daily fractions) and concomitant infused fluorouracil (225 mg/m 2 /d) either alone (arm A, n = 379) or combined with oxaliplatin (60 mg/m 2 weekly × 6; arm B, n = 368). Overall survival is the primary end point. A protocol-planned analysis of response to preoperative treatment is reported here. Results: Grade 3 to 4 adverse events during preoperative treatment were more frequent with oxaliplatin plus fluorouracil and radiation than with radiation and fluorouracil alone (24% v 8% of treated patients; P < .001). In arm B, 83% of the patients treated with oxaliplatin had five or more weekly administrations. Ninety-one percent, compared with 97% in the control arm, received ≥ 45 Gy (P < .001). Ninety-six percent versus 95% of patients underwent surgery with similar rates of abdominoperineal resections (20% v 18%, arm A v arm B). The rate of pathologic complete responses was 16% in both arms (odds ratio = 0.98; 95% CI, 0.66 to 1.44; P = .904). Twenty-six percent versus 29% of patients had pathologically positive lymph nodes (arm A v arm B; P = .447), 46% versus 44% had tumor infiltration beyond the muscularis propria (P = .701), and 7% versus 4% had positive circumferential resection margins (P = .239). Intra-abdominal metastases were found at surgery in 2.9% versus 0.5% of patients (arm A v arm B; P = .014). Conclusion: Adding oxaliplatin to fluorouracil-based preoperative chemoradiotherapy significantly increases toxicity without affecting primary tumor response. Longer follow-up is needed to assess the impact on efficacy end points.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1200/jco.2010.34.4911

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Preoperative versus Postoperative Chemoradiotherapy for Rectal Cancer
Sauer, R., Becker, H., Hohenberger, W., Rödel, C., Wittekind, C., Fietkau, R., Martus, P., Tschmelitsch, J., Hager, E., Hess, C. F., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040694 · Cited by 6,050
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer
de Gramont, A., Figer, A., Seymour, M., Homerin, M., Hmissi, A., Cassidy, J., Boni, C., Cortes-Funes, H., Cervantes, A., Freyer, G., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.16.2938 · Cited by 3,815
Self-citation
Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer
André, T., Boni, C., Mounedji-Boudiaf, L., Navarro, M., Tabernero, J. M., Hickish, T., Topham, C., Zaninelli, M., Clingan, P. R., Bridgewater, J. A., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032709 · Cited by 3,694
Chemotherapy with Preoperative Radiotherapy in Rectal Cancer
Bosset, J.-F., Collette, L., Calais, G., Mineur, L., Maingon, P., Radosevic-Jelic, L., Daban, A., Bardet, E., Beny, A., & Ollier, J.-C. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060829 · Cited by 2,688
Preoperative Radiotherapy With or Without Concurrent Fluorouracil and Leucovorin in T3-4 Rectal Cancers: Results of FFCD 9203
Gérard, J.-P., Conroy, T., Bonnetain, F., Bouché, O., Chapet, O., Closon-Dejardin, M.-T., Untereiner, M., Leduc, B., Francois, É., Maurel, J., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.7629 · Cited by 1,731
Pathological features of rectal cancer after preoperative radiochemotherapy
Dworak, O., Keilholz, L., & Hoffmann, A. (1997) · International Journal of Colorectal Disease · doi:10.1007/s003840050072 · Cited by 1,344
Common toxicity criteria: version 2.0. an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy
Trotti, A., Byhardt, R. W., Stetz, J., Gwede, C. K., Corn, B. W., Fu, K. K., Gunderson, L. L., McCormick, B. L., Morris∫, M., Rich, T. A., et al. (2000) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(99)00559-3 · Cited by 805
Comparison of Two Neoadjuvant Chemoradiotherapy Regimens for Locally Advanced Rectal Cancer: Results of the Phase III Trial ACCORD 12/0405-Prodige 2
Gérard, J.-P., Azria, D., Gourgou-Bourgade, S., Martel-Laffay, I., Hennequin, C., Etienne, P.-L., Vendrely, V., François, E., de La Roche, G., Bouché, O., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.8376 · Cited by 747
Enhanced Tumorocidal Effect of Chemotherapy With Preoperative Radiotherapy for Rectal Cancer: Preliminary Results—EORTC 22921
Bosset, J.-F., Calais, G., Mineur, L., Maingon, P., Radošević-Jelić, L., Daban, A., Bardet, É., Beny, A., Briffaux, A., & Collette, L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.113 · Cited by 594
Neoadjuvant Capecitabine and Oxaliplatin Followed by Synchronous Chemoradiation and Total Mesorectal Excision in Magnetic Resonance Imaging–Defined Poor-Risk Rectal Cancer
Chau, I., Brown, G. M., Cunningham, D., Tait, D., Wotherspoon, A. C., Norman, A. R., Tebbutt, N. C., Hill, M. E., Ross, P. J., Massey, A., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.4875 · Cited by 472

Flagged first, then by citations

Show all 29 references

Research works printed but not linked: 1

LH Sobin, CH Wittekind : International Union Against Cancer (UICC) TNM classification of malignant tumours 1997 5th ed New York, NY John Wiley & Sons

Sorted by citations

Items 201–300 of 764

Response of liver metastases to preoperative radiochemotherapy in patients with locally advanced rectal cancer and resectable synchronous liver metastases
Manceau, G., Brouquet, A., Bachet, J., Penna, C., Hajjam, M. E., Rougier, P. R., Nordlinger, B., & Benoist, S. (2013) · Surgery · doi:10.1016/j.surg.2013.02.010 · Cited by 23
The Neoadjuvant Treatment of Rectal Cancer: A Review
Nussbaum, N. C., & Altomare, I. P. (2015) · Current Oncology Reports · doi:10.1007/s11912-014-0434-9 · Cited by 22
Evaluation of capecitabine and oxaliplatin administered prior to and then concomitant to radiotherapy in high risk locally advanced rectal cancer
Gao, Y., An, X., Sun, W., Cai, J., Cai, M., Kong, L., Lin, J., Liu, G., Tang, J.-H., Wu, X., et al. (2013) · Journal of Surgical Oncology · doi:10.1002/jso.23516 · Cited by 23
Recent advances of neoadjuvant chemoradiotherapy in rectal cancer: Future treatment perspectives
Yamashita, K., Matsuda, T., Hasegawa, H., Mukohyama, J., Arimoto, A., Tanaka, T., Yamamoto, M., Matsuda, Y., Kanaji, S., Nakamura, T., et al. (2018) · Annals of Gastroenterological Surgery · doi:10.1002/ags3.12213 · Cited by 23
Short- and Long-Term Quality of Life and Bowel Function in Patients With MRI-Defined, High-Risk, Locally Advanced Rectal Cancer Treated With an Intensified Neoadjuvant Strategy in the Randomized Phase 2 EXPERT-C Trial
Sclafani, F., Peckitt, C., Cunningham, D., Tait, D., Giralt, J., Glimelius, B. L. G., Roselló, S., Bateman, A. R., Hickish, T., Tabernero, J. M., et al. (2015) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2015.03.038 · Cited by 22
Nonoperative management of rectal cancer
Torok, J. A., Palta, M., Willett, C. G., & Czito, B. G. (2015) · Cancer · doi:10.1002/cncr.29735 · Cited by 22
Low prevalence of deficient mismatch repair (dMMR) protein in locally advanced rectal cancers (LARC) and treatment outcomes
Ostwal, V. S., Pande, N., Engineer, R. Z., Saklani, A. P., Desouza, A. L., Ramadwar, M. R., Sawant, S., Mandavkar, S., Shrirangwar, S., Kataria, P., et al. (2018) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2018.10.01 · Cited by 23
Increased Levels of Genomic Instability and Mutations in Homologous Recombination Genes in Locally Advanced Rectal Carcinomas
do Canto, L. M., Larsen, S. J., Kupper, B. E. C., Begnami, M. D. F. D. S., Scapulatempo‐Neto, C., Petersen, A. H., Aagaard, M. M., Baumbach, J., Aguiar, S., & Rogatto, S. R. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00395 · Cited by 22
SEOM-GEMCAD-TTD clinical guidelines for localized rectal cancer (2021)
Capdevila, J., Gómez, M. A., Guillot, M., Páez, D., Pericay, C., Safont, M. J., Tarazona, N., Vera, R., Vidal, J., & Sastre, J. (2022) · Clinical & Translational Oncology · doi:10.1007/s12094-022-02816-9 · Cited by 22
A deep neural network predictor to predict the sensitivity of neoadjuvant chemoradiotherapy in locally advanced rectal cancer
Liu, Y., Shi, J., Liu, W., Tang, Y., Shu, X., Wang, R., Chen, Y., Shi, X., Jin, J., & Li, D. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216641 · Cited by 22
Surgery with versus without preoperative concurrent chemoradiotherapy for mid/low rectal cancer: an interim analysis of a prospective, randomized trial
Fan, W.-H., Wang, F.-L., Lu, Z., Pan, Z.-Z., Li, L., Gao, Y.-H., Chen, G., Wu, X.-J., Ding, P.-R., Zeng, Z., et al. (2015) · 癌症：英文版 · doi:10.1186/s40880-015-0024-8 · Cited by 22
Phase II study of preoperative bevacizumab, capecitabine and radiotherapy for resectable locally-advanced rectal cancer
García, M., Martinez–Villacampa, M., Santos, C., Navarro, V., Teulé, À., Losa, F., Pisa, A., Cambray, M., Soler, G., Lema, L., et al. (2015) · BMC Cancer · doi:10.1186/s12885-015-1052-0 · Cited by 22
Comparison between magnetic resonance imaging and rigid rectoscopy in the preoperative identification of intra‐ and extraperitoneal rectal cancer
Paparo, F., Puppo, C., Montale, A., Bacigalupo, L., Pascariello, A., Clavarezza, M., Binda, C., Rollandi, G. A., & Binda, G. A. (2014) · Colorectal Disease · doi:10.1111/codi.12698 · Cited by 22
Comparison of volumetric-modulated arc therapy using simultaneous integrated boosts (SIB-VMAT) of 45 Gy/55 Gy in 25 fractions with conventional radiotherapy in preoperative chemoradiation for rectal cancers: a propensity score case-matched analysis
Yamashita, H., Ishihara, S., Nozawa, H., Kawai, K., Kiyomatsu, T., Okuma, K., Abe, O., Watanabe, T., & Nakagawa, K. (2017) · Radiation Oncology · doi:10.1186/s13014-017-0894-9 · Cited by 22
Nomogram for predicting pathological complete response and tumor downstaging in patients with locally advanced rectal cancer on the basis of a randomized clinical trial
Zhang, J., Cai, Y., Xie, X., Hu, H., Ling, J., Wu, Z., Lan, P., Wu, X., Huang, M., Wang, H., et al. (2020) · Gastroenterology report · doi:10.1093/gastro/goz073 · Cited by 22
Long-Term Outcome of Oxaliplatin and Capecitabine (XELOX) Concomitant with Neoadjuvant Radiotherapy and Extended to the Resting Period in High Risk Locally Advanced Rectal Cancer
Tang, J., Wu, X., Bai, Y., Gao, Y., Wu, J., Kong, L.-H., Lin, J., Wan, D., Pan, Z., & Ding, P. (2018) · Journal of Cancer · doi:10.7150/jca.23874 · Cited by 22
Management of Rectal Cancer
Schlechter, B. L. (2022) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2022.03.002 · Cited by 21
Human epidermal growth factor receptor‐2 expression in locally advanced rectal cancer: Association with response to neoadjuvant therapy and prognosis
Meng, X., Wang, R., Huang, Z., Zhang, J., Feng, R., Xu, X., Zhu, K., Dou, X., Dong, C., & Yu, J. (2014) · Cancer Science · doi:10.1111/cas.12421 · Cited by 21
Preoperative Chemoradiation With VMAT-SIB in Rectal Cancer: A Phase II Study
Picardi, V., Macchia, G., Guido, A., Giaccherini, L., Deodato, F., Farioli, A., Cilla, S., Compagnone, G., Ardizzoni, A., Cuicchi, D., et al. (2016) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2016.06.004 · Cited by 22
Addition of oxaliplatin to neoadjuvant radiochemotherapy in MRI‐defined T3, T4 or N+ rectal cancer: a randomized clinical trial
Haddad, P., Miraie, M., Farhan, F., Fazeli, M., Alikhassi, A., Maddah-Safai, A., Aghili, M., Kalaghchi, B., & Babaei, M. (2017) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.12675 · Cited by 21
Local excision in rectal cancer patients with major or complete clinical response after neoadjuvant therapy: a case-matched study
Bushati, M., Pucciarelli, S., Gennaro, N., Maretto, I., Toppan, P., Perin, A., Urso, E. D. L., Bagatella, A., & Spolverato, G. (2019) · International Journal of Colorectal Disease · doi:10.1007/s00384-019-03420-0 · Cited by 21
The status of targeted agents in the setting of neoadjuvant radiation therapy in locally advanced rectal cancers.
Glynne‐Jones, R., Hadaki, M., & Harrison, M. (2013) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2078-6891.2013.037 · Cited by 21
Surgical oncology in the age of multimodality therapy for cancer of the upper and lower gastrointestinal tract
Neumann, P., Berlet, M., & Friess, H. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2021.1868991 · Cited by 23
Locally advanced rectal adenocarcinoma: Treatment sequences, intensification, and rectal organ preservation
Bigness, A., Imanirad, I., Şahin, İ. H., Xie, H., Frakes, J. M., Hoffe, S. E., Laskowitz, D., & Felder, S. I. (2021) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21661 · Cited by 22
Is There a Benefit of Oxaliplatin in Combination with Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer? An Updated Meta-Analysis
Guetz, G. D., Landre, T., Bollet, M. A., Mathonnet, M., & Quéro, L. (2021) · Cancers · doi:10.3390/cancers13236035 · Cited by 20
Preoperative Radiation Therapy With Concurrent Capecitabine, Bevacizumab, and Erlotinib for Rectal Cancer: A Phase 1 Trial
Das, P., Eng, C., Rodrı́guez-Bigas, M. A., Chang, G. J., Skibber, J. M., You, Y. N., Maru, D. M., Munsell, M. F., Clemons, M. V., Kopetz, S., et al. (2013) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2013.10.034 · Cited by 20
Optimizing Neoadjuvant Therapy for Rectal Cancer With Oxaliplatin
Martin, L. K., & Bekaii‐Saab, T. (2013) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2013.0041 · Cited by 20
Chemotherapy Alone for Patients With Stage II/III Rectal Cancer Undergoing Radical Surgery
Algizawy, S. M., Essa, H. H., & Ahmed, B. M. (2015) · The Oncologist · doi:10.1634/theoncologist.2015-0038 · Cited by 20
Korean Society of Coloproctology (KSCP) trial of cONsolidation Chemotherapy for Locally advanced mid or low rectal cancer after neoadjUvant concurrent chemoraDiothErapy: a multicenter, randomized controlled trial (KONCLUDE)
Kim, C. W., Kang, B. M., Kim, I. Y., Kim, J., Park, S. J., Park, W. C., Bae, K. B., Bae, B., Baek, S. K., Baik, S. H., et al. (2018) · BMC Cancer · doi:10.1186/s12885-018-4466-7 · Cited by 20
Sandwich-like neoadjuvant therapy with bevacizumab for locally advanced rectal cancer: a phase II trial
Xiao, J., Chen, Z., Li, W., Yang, Z., Huang, Y. J., Zheng, J., Deng, Y., Wang, L., Ren, D., Peng, J., et al. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2763-2 · Cited by 20
Long-course neoadjuvant chemoradiotherapy with versus without a concomitant boost in locally advanced rectal cancer: a randomized, multicenter, phase II trial (FDRT-002)
Wang, J., Guan, Y., Gu, W., Yan, S., Zhou, J., Huang, D., Tong, T., Li, C., Cai, S., Zhang, Z., et al. (2019) · Radiation Oncology · doi:10.1186/s13014-019-1420-z · Cited by 20
Curative immune checkpoint inhibitors therapy in patients with mismatch repair-deficient locally advanced rectal cancer: a real-world observational study
Tosi, F., Salvatore, L., Tamburini, E., Artale, S., Lonardi, S., Marchetti, S., Pastorino, A., Pietrantonio, F., Puccini, A., Llimpe, F. L. R., et al. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.103929 · Cited by 19
Self-citation
Prospective phase II trial of nimotuzumab in combination with radiotherapy and concurrent capecitabine in locally advanced rectal cancer
Jin, T., Zhu, Y., Luo, J., Zhou, N., Li, D., Hai-xin, J., Fan, Y., Liu, Y., Zhu, Y.-P., Feng, H.-Y., et al. (2015) · International Journal of Colorectal Disease · doi:10.1007/s00384-014-2097-2 · Cited by 19
MRI and FDG-PET for Assessment of Response to Neoadjuvant Chemotherapy in Locally Advanced Rectal Cancer
Aiba, T., Uehara, K., Nihashi, T., Tsuzuki, T., Yatsuya, H., Yoshioka, Y., Kato, K., & Nagino, M. (2014) · Annals of Surgical Oncology · doi:10.1245/s10434-014-3538-4 · Cited by 20
Use of sequential endorectal US to predict the tumor response of preoperative chemoradiotherapy in rectal cancer
Li, N., Dou, L., Zhang, Y., Jin, J., Wang, G., Xiao, Q., Li, Y., Wang, X., Ren, H., Fang, H., et al. (2016) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2016.06.042 · Cited by 20
Acute toxicity and surgical complications after preoperative (chemo)radiation therapy for rectal cancer in patients with inflammatory bowel disease
Bosch, S. L., van Rooijen, S. J., Bökkerink, G. M. J., Braam, H. J., Derikx, L. A. A. P., Poortmans, P. M., Marijnen, C. A. M., Nagtegaal, I. D., & de Wilt, J. H. W. (2017) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2017.02.009 · Cited by 21
Prognostic value of pretreatment level of carcinoembryonic antigen on tumour downstaging and early occurring metastasis in locally advanced rectal cancer following neoadjuvant radiotherapy (30 Gy in 10 fractions)
Wang, L., Zhong, X. ‐., Peng, Y., Li, Z., & Gu, J. F. (2013) · Colorectal Disease · doi:10.1111/codi.12354 · Cited by 18
Comparison of guidelines on rectal cancer: exception proves the rule?
Dou, R., He, S., Deng, Y., & Wang, J. (2021) · Gastroenterology report · doi:10.1093/gastro/goab034 · Cited by 18
Current perspectives on preoperative integrated treatments for locally advanced rectal cancer: a review of agreement and controversies.
Cellini, F., & Valentini, V. (2012) · PubMed · Cited by 18
Early increase in circulating carbonic anhydrase IX during neoadjuvant treatment predicts favourable outcome in locally advanced rectal cancer
Hektoen, H. H., Flatmark, K., Andersson, Y., Dueland, S., Redalen, K. R., & Ree, A. H. (2015) · BMC Cancer · doi:10.1186/s12885-015-1557-6 · Cited by 18
Intensified neoadjuvant chemoradiotherapy in locally advanced rectal cancer – impact on long-term quality of life
Kripp, M., Wieneke, J. K., Kienle, P., Welzel, G., Brade, J., Horisberger, K., Wenz, F. K., Post, S., Gencer, D., Hofmann, W.-K., et al. (2012) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2012.02.002 · Cited by 18
Phase 2 Neoadjuvant Treatment Intensification Trials in Rectal Cancer: A Systematic Review
Teo, M. T. W., McParland, L., Appelt, A. L., & Sebag‐Montefiore, D. (2017) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2017.09.042 · Cited by 19
Phase II Trial Using a Combination of Oxaliplatin, Capecitabine, and Celecoxib with Concurrent Radiation for Newly Diagnosed Resectable Rectal Cancer
Araujo-Mino, E. P., Patt, Y. Z., Murray-Krezan, C. M., Hanson, J. A., Bansal, P., Liem, B., Rajput, A., Fekrazad, M. H., Heywood, G., & Lee, F.-C. (2017) · The Oncologist · doi:10.1634/theoncologist.2017-0474 · Cited by 18
Genotype-driven phase I study of weekly irinotecan in combination with capecitabine-based neoadjuvant chemoradiation for locally advanced rectal cancer
Zhu, J. Y., Li, X., Shen, Y., Guan, Y., Gu, W., Lian, P., Sheng, W., Cai, S., & Zhang, Z. (2017) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2017.11.026 · Cited by 18
Neoadjuvant chemoradiation for locally advanced rectal cancer: a systematic review of the literature with network meta-analysis
Chen, M., Chen, L.-Z., Xu, L., Zhang, J.-S., & Song, X. (2019) · Cancer Management and Research · doi:10.2147/cmar.s189445 · Cited by 18
Surgical treatment following neoadjuvant chemoradiotherapy in locally advanced rectal cancer
Huang, M., Huang, C., & Wang, J. (2019) · The Kaohsiung Journal of Medical Sciences · doi:10.1002/kjm2.12161 · Cited by 18
Advances for achieving a pathological complete response for rectal cancer after neoadjuvant therapy
Cui, J. T., Fang, H., Zhang, L., Wu, Y., & Zhang, H. (2016) · Chronic Diseases and Translational Medicine · doi:10.1016/j.cdtm.2016.06.001 · Cited by 17
A multicenter phase II study of preoperative chemoradiotherapy with S-1 plus oxaliplatin for locally advanced rectal cancer (SHOGUN trial)
Matsusaka, S., Ishihara, S., Kondo, K., Horie, H., Uehara, K., Oguchi, M., Murofushi, K. N., Ueno, M., Mizunuma, N., Shimbo, T., et al. (2015) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2015.08.002 · Cited by 17
Pathological Complete Response After Neoadjuvant Therapy for Rectal Cancer and the Role of Adjuvant Therapy
Nelson, V. M., & Benson, A. B. (2013) · Current Oncology Reports · doi:10.1007/s11912-013-0297-5 · Cited by 18
Selecting Patients With Locally Advanced Rectal Cancer for Neoadjuvant Treatment Strategies
Dewdney, A., Cunningham, D., & Chau, I. (2013) · The Oncologist · doi:10.1634/theoncologist.2013-0022 · Cited by 18
Combination of Novel Agents with Radiotherapy to Treat Rectal Cancer
Greenhalgh, T. A., Dearman, C., & Sharma, R. A. (2015) · Clinical Oncology · doi:10.1016/j.clon.2015.11.002 · Cited by 17
Preoperative Chemoradiotherapy for Rectal Cancer in Patients Aged 75 Years and Older: Acute Toxicity, Compliance with Treatment, and Early Results
Guimas, V., Boustani, J., Schipman, B., Lescut, N., Puyraveau, M., Bosset, J.-F., & Servagi-Vernat, S. (2016) · Drugs & Aging · doi:10.1007/s40266-016-0367-0 · Cited by 17
A multicenter phase I study of preoperative chemoradiotherapy with S-1 and irinotecan for locally advanced lower rectal cancer (SAMRAI-1)
Sato, T., Hayakawa, K., Tomita, N., Noda, M., Kamikonya, N., Watanabe, T., Kato, D., Sakai, Y., Hiraoka, M., Shimada, M., et al. (2016) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2016.06.002 · Cited by 17
Controversies in the multimodality management of locally advanced rectal cancer
Beveridge, R. D., Akhoundova, D., Bruixola, G., & Aparicio, J. (2017) · Medical Oncology · doi:10.1007/s12032-017-0964-8 · Cited by 19
Relationship Between Expression of Proteins ERCC1, ERCC2, and XRCC1 and Clinical Outcomes in Patients with Rectal Cancer Treated with FOLFOX‐Based Preoperative Chemoradiotherapy
Huang, M., Huang, J., Huang, C., Lin, C., Tsai, H., Huang, C., Chai, C., Lin, C., & Wang, J. (2017) · World Journal of Surgery · doi:10.1007/s00268-017-4070-z · Cited by 17
Preoperative Volumetric Modulated Arc Therapy With Simultaneous Integrated Boost for Locally Advanced Distal Rectal Cancer
Yang, Y., Liu, Q., Jia, B., Du, X., Dai, G., Liu, H., Chen, J., Zeng, M., Wen, K., Zhu, Y., et al. (2019) · Technology in Cancer Research & Treatment · doi:10.1177/1533033818824367 · Cited by 16
Treatment sequencing for simultaneous colorectal liver metastases
Krell, R. W., & D'Angelica, M. I. (2019) · Journal of Surgical Oncology · doi:10.1002/jso.25424 · Cited by 18
Adjuvant chemotherapy in rectal cancer: state of the art and future perspectives
Glimelius, B. L. G. (2020) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000641 · Cited by 17
Phase II study of preoperative chemoradiation with S‐1 plus oxaliplatin in patients with locally advanced rectal cancer
Lee, E. M., Hong, Y. S., Kim, K., Lee, J., Kim, S. Y., Park, Y. S., Choi, D. H., Kim, J. H., Lim, S., Yu, C. S., et al. (2012) · Cancer Science · doi:10.1111/cas.12041 · Cited by 17
Impact of Lymph Node Ratio on Oncologic Outcomes in ypStage III Rectal Cancer Patients Treated with Neoadjuvant Chemoradiotherapy followed by Total Mesorectal Excision, and Postoperative Adjuvant Chemotherapy
Koo, T., Song, C., Js, K., Kim, K., Chie, E. K., Kang, S., Lee, K., Kim, J. H., Jeong, S., & Kim, T. (2015) · PLoS ONE · doi:10.1371/journal.pone.0138728 · Cited by 17
UGT 1A1 polymorphisms in rectal cancer associated with the efficacy and toxicity of preoperative chemoradiotherapy using irinotecan
Kimura, K., Yamano, T., Igeta, M., Imada, A., Jihyung, S., Babaya, A., Hamanaka, M., Kobayashi, M., Tsukamoto, K., Noda, M., et al. (2018) · Cancer Science · doi:10.1111/cas.13807 · Cited by 16
Phase I Trial of Trametinib with Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer
Wu, C. S.-Y., Williams, T. M., Robb, R. N., Webb, A., Wei, L., Chen, W., Mikhail, S., Ciombor, K. K., Cardin, D. B., Timmers, C. D., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-4193 · Cited by 17
Rectal cancer - French intergroup clinical practice guidelines for diagnosis, treatment, and follow-up (TNCD, SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, SFP, RENAPE, SNFCP, AFEF, SFR, and GRECCAR)
Cotte, E., Arquilliere, J., Artru, P., Bachet, J., Benhaïm, L., Bibeau, F., Christou, N., Conroy, T., Doyen, J., Hoeffel, C. C., et al. (2024) · Digestive and Liver Disease · doi:10.1016/j.dld.2024.12.004 · Cited by 16
Neoadjuvant Chemotherapy Without Radiotherapy for Locally Advanced Rectal Cancer
Sclafani, F., & Cunningham, D. (2014) · Future Oncology · doi:10.2217/fon.14.127 · Cited by 16
Maintenance BEZ235 Treatment Prolongs the Therapeutic Effect of the Combination of BEZ235 and Radiotherapy for Colorectal Cancer
Chen, Y., Wang, C., Wei, M., Tzeng, Y.-S., Lan, K.-H., Cheng, A., & Kuo, S. (2019) · Cancers · doi:10.3390/cancers11081204 · Cited by 16
Tumor marker recovery rather than major pathological response is a preferable prognostic factor in patients with pancreatic ductal adenocarcinoma with preoperative therapy
Yamada, S., Yokoyama, Y., Sonohara, F., Yamaguchi, J., Takami, H., Hayashi, M., Onoe, S., Fujii, T., Nagino, M., & Kodera, Y. (2020) · Journal of Hepato-Biliary-Pancreatic Sciences · doi:10.1002/jhbp.748 · Cited by 16
Phase II Study of Preoperative Treatment with External Radiotherapy Plus Panitumumab in Low-Risk, Locally Advanced Rectal Cancer (RaP Study/STAR-03)
Pinto, C., Bisceglie, M. D., Fabio, F. D., Bochicchio, A. M., Latiano, T. P., Cordio, S. S., Rosati, G., Aschele, C., Marino, A., Bergamo, F., et al. (2018) · The Oncologist · doi:10.1634/theoncologist.2017-0484 · Cited by 16
Self-citation
Transcatheter rectal arterial chemoembolization with oxaliplatin plus S-1 concurrent chemoradiotherapy can improve the pathological remission rate in locally advanced rectal cancer: a comparative study
Yang, B., Shan, J., Feng, Y., Dai, N., Li, M., Chen, C., He, S., Wang, G., Xiao, H., Li, C., et al. (2020) · Radiation Oncology · doi:10.1186/s13014-020-01540-4 · Cited by 15
Neoadjuvant Therapy for Rectal Cancer
Quezada-Díaz, F., & Smith, J. J. (2022) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2021.11.008 · Cited by 15
Strategies to Optimize Treatment for Locally Advanced Rectal Cancer
Hu, X., Xue, Z., He, K., Tian, Y., Chen, Y., Zhao, M., Yu, J., & Yue, J. (2022) · Cancers · doi:10.3390/cancers15010219 · Cited by 15
Short-Course Radiation Versus Long-Course Chemoradiation for Rectal Cancer
Minsky, B. D., Rödel, C. M., & Valentini, V. (2012) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2012.0129 · Cited by 15
Does the Addition of Cetuximab to Radiochemotherapy Improve Outcome of Patients with Locally Advanced Rectal Cancer? Long-Term Results from Phase II Trials
Kripp, M., Horisberger, K., Mai, S., Kienle, P., Gaiser, T., Post, S., Wenz, F. K., Merx, K., & Hofheinz, R. (2015) · Gastroenterology Research and Practice · doi:10.1155/2015/273489 · Cited by 15
Multidisciplinary Approach to Rectal Cancer: Are we Ready for Selective Treatment Strategies?
Avallone, A., Aloj, L., Delrio, P., Pecori, B., Leone, A., Tatangelo, F., Perri, F., Petrillo, A., Scott, N., & Budillon, A. (2013) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/18715206113139990123 · Cited by 15
Trends in combined radio-chemotherapy for locally advanced rectal cancer: a survey among radiation oncology centers of Sicily region on behalf of AIRO
Spatola, C., Privitera, G., Milazzotto, R., Tocco, A., Acquaviva, G., Marletta, F., Marino, L., Grazia, A. D., Salvo, R., Cartia, G., et al. (2019) · La radiologia medica · doi:10.1007/s11547-019-01007-x · Cited by 16
Addressing the variation in adjuvant chemotherapy treatment for colorectal cancer: Can a regional intervention promote national change?
Taylor, J., Swinson, D., Seligmann, J. F., Birch, R. J., Dewdney, A., Brown, V. A., Dent, J., Rossington, H., Quirke, P., Morris, E. J. A., et al. (2020) · International Journal of Cancer · doi:10.1002/ijc.33261 · Cited by 15
Outcomes of neoadjuvant chemoradiotherapy followed by radical resection for T4 colorectal cancer
Huang, C., Huang, C., Ma, C., Tsai, H., Su, W., Chang, T., Huang, M., & Wang, J. (2020) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v12.i12.1428 · Cited by 17
Multimodal Rectal Cancer Treatment: In Some Cases, Less May Be More
García‐Aguilar, J., Glynne‐Jones, R., & Schrag, D. (2016) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_159221 · Cited by 16
Implications for determining the optimal treatment for locally advanced rectal cancer in elderly patients aged 75 years and older
Wan, J.-F., Zhu, J. Y., Li, G., Sun, W.-J., & Zhang, Z. (2015) · Oncotarget · doi:10.18632/oncotarget.4599 · Cited by 15
Neoadjuvant Treatment in Rectal Cancer: Do We Always Need Radiotherapy–or Can We Risk Assess Locally Advanced Rectal Cancer Better?
Glynne‐Jones, R. (2012) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-642-31629-6_2 · Cited by 15
Phase II randomized trial of capecitabine with bevacizumab and external beam radiation therapy as preoperative treatment for patients with resectable locally advanced rectal adenocarcinoma: long term results
on behalf of the Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD), Salazar, R., Capdevila, J., Manzano, J. L., Pericay, C., Martinez–Villacampa, M., López, C., Losa, F., Safont, M. J., Gómez‐España, A., et al. (2020) · BMC Cancer · doi:10.1186/s12885-020-07661-z · Cited by 15
Neoadjuvant Treatment for Locally Advanced Rectal Cancer: Current Status and Future Directions
Iwamoto, M., Ueda, K., & Kawamura, J. (2025) · Cancers · doi:10.3390/cancers17152540 · Cited by 17
Preoperative chemoradiotherapy versus surgery alone for advanced low rectal cancer: a large multicenter cohort study in Japan
Akagi, T., Inomata, M., Fujishima, H., Fukuda, M., Konishi, T., Tsukamoto, S., Teraishi, F., Ozawa, H., Tanaka, K., Hida, K., et al. (2020) · Surgery Today · doi:10.1007/s00595-020-02034-2 · Cited by 14
Combinatorial Approaches for Chemotherapies and Targeted Therapies With Radiation: United Efforts to Innovate in Patient Care
Jabbour, S. K., Kumar, R. N., Anderson, B. M., Chino, J., Jethwa, K. R., McDowell, L. J., Lo, A., Owen, D., Pollom, E. L., Tree, A. C., et al. (2024) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2024.01.010 · Cited by 14
Selective Use of Preoperative Chemoradiotherapy for T3 Rectal Cancer Can Be Justified: Analysis of Local Recurrence
Baek, S. J., Kim, S. H., Kwak, J., Cho, J., Shin, J., Amar, A. H. Y., & Kim, J. (2012) · World Journal of Surgery · doi:10.1007/s00268-012-1792-9 · Cited by 14
Multimodal treatment strategies for locally advanced rectal cancer
Weber, G. F., Rosenberg, R., Murphy, J. E., Büschenfelde, C. M. Z., & Friess, H. (2012) · Expert Review of Anticancer Therapy · doi:10.1586/era.12.3 · Cited by 14
Applying Nanotherapeutics to Improve Chemoradiotherapy Treatment for Cancer
Caster, J. M., & Wang, A. Z. (2017) · Therapeutic Delivery · doi:10.4155/tde-2017-0043 · Cited by 14
Contemporary management of locally advanced rectal cancer: Resolving issues, controversies and shifting paradigms
Nacion, A. J. D., Park, Y. Y., & Kim, N. K. (2018) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2018.01.14 · Cited by 14
Pattern and Management of Recurrence of Mid-Low Rectal Cancer After Neoadjuvant Intensity-Modulated Radiotherapy: Single-Center Results of 687 Cases
Wu, A., Cai, Y., Li, Y., Wang, L., Li, Z., Sun, Y., & Ji, J. (2018) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2018.01.006 · Cited by 13
The high pCR rate of sandwich neoadjuvant treatment in locally advanced rectal cancer may translate into a better long-term survival benefit: 5-year outcome of a Phase II clinical trial
Hu, Y.-H., Wei, J.-W., Chang, H., Xiao, W., Lin, J.-Z., Cai, M.-Y., Cai, P., Kong, L.-H., Chen, G., Pan, Z., et al. (2018) · Cancer Management and Research · doi:10.2147/cmar.s168573 · Cited by 14
Potential predictive biomarkers in locally advanced rectal cancer treated with preoperative chemo-radiotherapy.
Bottarelli, L., Angelis, G. L. D., Azzoni, C., Mario, F. D., de’Angelis, N., Leandro, G., Fornaroli, F., Gaiani, F., & Negri, F. (2018) · Acta bio-medica dell'Ateneo parmense/Acta biomedica · doi:10.23750/abm.v89i9-s.7881 · Cited by 14
High-dose radiotherapy (60 Gy) with oral UFT/folinic acid and escalating doses of oxaliplatin in patients with non-resectable locally advanced rectal cancer (LARC): A phase I trial
Vestermark, L. W., Jensen, H. A., & Pfeiffer, P. (2012) · Acta Oncologica · doi:10.3109/0284186x.2011.652740 · Cited by 14
Combination chemotherapy versus single-agent chemotherapy during preoperative chemoradiation for resectable rectal cancer
Resende, H. M., Jacob, L. F. P., Quinellato, L. V., Matos, D., & da Silva, E. M. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008531.pub2 · Cited by 15
Long-term results of a multicenter phase II study of preoperative chemoradiotherapy with S-1 plus oxaliplatin for locally advanced rectal cancer (JACCRO CC-04: SHOGUN Trial)
Kondo, K., Matsusaka, S., Ishihara, S., Horie, H., Uehara, K., Oguchi, M., Murafushi, K., Ueno, M., Mizunuma, N., Shimbo, T., et al. (2019) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2019.02.006 · Cited by 14
Two Cases of Pathological Complete Response to Neoadjuvant Chemoradiation Therapy in Pancreatic Cancer
Fujii‐Nishimura, Y., Nishiyama, R., Kitago, M., Masugi, Y., Ueno, A., Aiura, K., Kawachi, S., Kawaida, M., Abe, Y., Shinoda, M., et al. (2015) · The Keio Journal of Medicine · doi:10.2302/kjm.2014-0014-cr · Cited by 14
Update and Debate Issues in Surgical Treatment of Middle and Low Rectal Cancer
Kim, N. K., Kim, M. S., & Alasari, S. (2012) · Journal of the Korean Society of Coloproctology · doi:10.3393/jksc.2012.28.5.230 · Cited by 14
Impact of age on efficacy of postoperative oxaliplatin-based chemotherapy in patients with rectal cancer after neoadjuvant chemoradiotherapy
Huang, X., Gao, P., Song, Y., Sun, J., Chen, X., Zhao, J., Ma, B., Wang, J., & Wang, Z.-N. (2016) · Oncotarget · doi:10.18632/oncotarget.7544 · Cited by 13
The 2017 Assisi Think Tank Meeting on rectal cancer: A positioning paper
Valentini, V., Marijnen, C. A. M., Beets, G. L., Bujko, K., Bari, B. D., Cervantes, A. M. R., Chiloiro, G., Coco, C., Gambacorta, M. A., Glynne‐Jones, R., et al. (2019) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2019.07.001 · Cited by 13
Preoperative chemoradiotherapy with capecitabine and triweekly oxaliplatin versus capecitabine monotherapy for locally advanced rectal cancer: a propensity-score matched study
Li, A., Huang, T., Zheng, R., Chi, P., Li, Z., Wang, X., & Xu, B. (2022) · BMC Cancer · doi:10.1186/s12885-022-09855-z · Cited by 13
Progress in the Treatment of Locally Advanced Clinically Resectable Rectal Cancer
Minsky, B. D. (2011) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2011.06.007 · Cited by 13
Outcome Reporting in Neoadjuvant Surgical Trials: A Systematic Review of the Literature and Proposals for New Standards
Blencowe, N., Chana, P., Whistance, R. N., Stevens, D. J., Wong, N. A. C. S., Falk, S. J., & Blazeby, J. M. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju217 · Cited by 13

Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial
Rödel, C. M., Graeven, U., Fietkau, R., Hohenberger, W., Hothorn, T., Arnold, D., Hofheinz, R., Ghadimi, M. B., Wolff, H. A., Lang-Welzenbach, M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00159-x · Cited by 736
Preoperative fluorouracil (FU)-based chemoradiation with and without weekly oxaliplatin in locally advanced rectal cancer: Pathologic response analysis of the Studio Terapia Adiuvante Retto (STAR)-01 randomized phase III trial
Aschele, C., Pinto, C., Cordio, S., Rosati, G., Tagliagambe, A., Artale, S., Rosetti, P., Lonardi, S., Boni, L., & Cionini, L. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.18s.cra4008 · Cited by 13
Self-citation
Final results of STAR-01: A randomized phase III trial comparing preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer.
Aschele, C., Lonardi, S., Cionini, L., Pinto, C., Cordio, S. S., Rosati, G., Bianchi, A. S., Tagliagambe, A., Frisinghelli, M., Zagonel, V., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.3521 · Cited by 42
Self-citation
Preoperative concomitant chemoradiotherapy with oxaliplatin and 5-fluorouracil in locally advanced rectal carcinoma
Djellali, L., Larbaoui, B., Boukerche, A., Ghazi, S. H., Chaiba, I., Meziane, N., Yekrou, D., & Youcef, D. F. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.e15108 · Cited by 1
A phase II study of oxaliplatin with 5-FU/folinic acid and concomitant radiotherapy as a preoperative treatment in patients with locally advanced rectal cancer.
Chitapanarux, I., Chitapanarux, T., Tharavichitkul, E., Mayurasakorn, S., Siriwittayakorn, P., Yamada, S., & Lorvidhaya, V. (2011) · PubMed Central · doi:10.2349/biij.7.4.e25 · Cited by 5

See all

Authors: Aschele, C., Cionini, L., Lonardi, S., Pinto, C., Cordio, S., Rosati, G., Artale, S., Tagliagambe, A., Ambrosini, G., Rosetti, P., Bonetti, A., Negru, M. E., Tronconi, M. C., Luppi, G., Silvano, G., Corsi, D. C., Bochicchio, A. M., Chiaulon, G., Gallo, M., & Boni, L.
Affiliations: Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT)
ORCID: Aschele, Carlo
Lonardi, Sara
Pinto, Carmine
Rosati, Gerardo
Bonetti, Andrea
Tronconi, Maria Chiara
Luppi, Gabriele
Silvano, Giovanni
Corsi, Domenico Cristiano
Bochicchio, Anna Maria
Boni, Luca
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2011-07-10
Volume: 29
Issue: 20
Pages: 2773-2780
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.2010.34.4911
OpenAlex: W2123712900
Cited by: 763
References: 29
Citations by year: 2026: 8 · 2025: 23 · 2024: 24 · 2023: 21 · 2022: 37 · 2021: 42 · 2020: 60 · 2019: 60 · 2018: 59 · 2017: 72 · 2016: 61 · 2015: 83 · 2014: 62 · 2013: 64 · 2012: 69
FWCI: 33.33
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
Funders: Amgen
Sanofi
Topics: Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
Health Sciences › Medicine › Surgery › Colorectal and Anal Carcinomas
Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
Keywords: locally advanced rectal cancer, neoadjuvant chemoradiotherapy, oxaliplatin, 5-fluorouracil, pelvic radiotherapy, pathological complete response, circumferential resection margin, lymph node metastasis, treatment toxicity, abdominoperineal resection, overall survival
MeSH terms: Oxaliplatin, Adenocarcinoma, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Female, Fluorouracil, Humans, Italy, Male, Middle Aged, Organoplatinum Compounds, Rectal Neoplasms, Survival Analysis, Dose Fractionation, Radiation, Neoadjuvant Therapy, Medication Adherence, Drug-Related Side Effects and Adverse Reactions

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Primary Tumor Response to Preoperative Chemoradiation With or Without Oxaliplatin in Locally Advanced Rectal Cancer: Pathologic Results of the STAR-01 Randomized Phase III Trial

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks